Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2Gynecologic 2Sarcoma 1Other solid neoplasm 1Lymphoid 1Head & Neck 1Genitourinary 1Endocrine 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Penile Neoplasms 1Ovarian Neoplasms 1Mesothelioma, Malignant 1Lung Neoplasms 1

Interventions

Cyclophosphamide 80Paclitaxel 53Trastuzumab 41Tamoxifen 40Doxorubicin 39Specimen Handling 35Docetaxel 35Magnetic Resonance Spectroscopy 34Radiotherapy 33Taxes 30Fluorouracil 26Chemotherapy, Adjuvant 26Carboplatin 24Epirubicin 22Biopsy 22Filgrastim 21Neoadjuvant Therapy 19Methotrexate 19aldesleukin 17Peripheral Blood Stem Cell Transplantation 16Bevacizumab 14Anastrozole 14exemestane 13Lapatinib 13veliparib 12CMF regimen 12sargramostim 11Goserelin 11Fulvestrant 11Capecitabine 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × BAY 1895344 × Breast × Clear all
NCT04491942 2026-04-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
74 enrolled
BreastGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Penile Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡